Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis

  • Yuriko Mori*
  • , Vasko Kramer
  • , Emil Novruzov
  • , Eduards Mamlins
  • , Manuel Röhrich
  • , René Fernández
  • , Horacio Amaral
  • , Cristian Soza-Ried
  • , Barbara Monje
  • , Eduardo Sabbagh
  • , Matías Florenzano
  • , Frederik L. Giesel
  • , Álvaro Undurraga
  • *Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

24 Citas (Scopus)

Resumen

Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. 68Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, 18F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [18F]FAPI-74 prospectively in a small patient cohort. Methods: Eight patients underwent both [18F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters. Results: We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung. Conclusion: The initial results confirm our assumption that [18F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.

Idioma originalInglés
Páginas (desde-hasta)1605-1611
Número de páginas7
PublicaciónEuropean Journal of Nuclear Medicine and Molecular Imaging
Volumen51
N.º6
DOI
EstadoPublicada - may. 2024

Nota bibliográfica

Publisher Copyright:
© The Author(s) 2023.

Huella

Profundice en los temas de investigación de 'Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis'. En conjunto forman una huella única.

Citar esto